Abattis Bioceuticals Corp. has arranged a non-brokered private placement of up to 12 million units of the company at a price of five cents per unit for gross proceeds of up to $600,000. Each unit will comprise one common share and one-half of one share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share for a period of one year at a price of 10 cents per share. The securities, when issued, will be subject to a four-month hold period. A finder's fee will be paid to eligible finders in relation to this financing in accordance with regulatory policies. The proceeds will be used for general working capital purposes.

The company is also pleased to advise that it has been added to the Marijuana Index. The index's website states: "The Marijuana Index is the first and only registered equity tracking index which monitors the performance, news and general pulse of qualified marijuana stocks or cannabis stocks. Weighted by market capitalization (as determined by common shares outstanding multiplied by last trade price), the index provides existing or prospective investors with a narrow and centralized view of these pioneering securities which are positioned in a multibillion dollar growth industry."

The company has negotiated debt settlement arrangements with two officers of the company in relation to an aggregate of $106,250 debt owed to them. Under the terms of the agreements, the company proposes to issue an aggregate of 2,125,000 shares at a deemed price of five cents per share. The securities, when issued, will be subject to a four-month hold period.

The company advises that 250,000 stock options have been granted to an officer of the company. These options are exercisable at a price of 10 cents per share for five years.

The company also clarifies that it completed the shares-for-debt transaction originally announced Nov. 28, 2013.

Mike Withrow, chief executive officer, stated: "We have come one step closer to achieving another key milestone in the company's plan to become federally licensed under the MMPR. This will crystallize our efforts to complete our international strategy, and be instrumental in delivering safe efficacious medicines and products that work."

We seek Safe Harbor.